Development asset linked to Zelgen Biopharmaceuticals in public FDA and regional records.
biotech · ALK-positive Non-small Cell Lung Cancer · Biliary Tract Carcinoma
Zelgen Biopharmaceuticals
Suzhou Zelgen Biopharmaceuticals Co.,Ltd
Zelgen Biopharmaceuticals drug portfolio — 7 indexed compounds with therapeutic class and molecular targets from public FDA and regional approval metadata.
Kunshan, CN HQ
8 Employees
NMPA registrant Type
Company details
- Status
- Public
- HQ
- Kunshan, CN
- Employees
- 8
- Programs
- 3
- Drugs
- 7
- Patents
- 0
Zelgen Biopharmaceuticals pipeline
Portfolio lens on 7 drugs and development assets — regulatory status, targets, and deep links to NovaPharmaNews drug profiles.
Zelgen Biopharmaceuticals drug portfolio — 7 indexed compounds with therapeutic class and molecular targets from public FDA and regional approval metadata.
Drug portfolio
-
-
Development asset linked to Zelgen Biopharmaceuticals in public FDA and regional records.
-
Development asset linked to Zelgen Biopharmaceuticals in public FDA and regional records.
-
Development asset linked to Zelgen Biopharmaceuticals in public FDA and regional records.
-
Development asset linked to Zelgen Biopharmaceuticals in public FDA and regional records.
-
Development asset linked to Zelgen Biopharmaceuticals in public FDA and regional records.
-
Development asset linked to Zelgen Biopharmaceuticals in public FDA and regional records.